Sort
39,280 grants matching “leukemia”
Environmental Oxygen Transitions and Aspergillosis Disease Progression
$520,089Robert Andrew Cramer · Dartmouth College · R01 · FY2019 · AI
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance
$520,007Omar Abdel-Wahab · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Kansas City Clinical Oncology Program CCOP
$520,000Rakesh Gaur · Nci Community Oncology Research Program · U10 · FY2009 · CA
Systems Biology of Tumor Progression and Drug Resistance
$520,000Andrea Califano · Columbia University Health Sciences · U01 · FY2013 · CA
Novel Regulation of Oncogenic NRAS Signaling in Myeloid Malignancies
$519,949Wei Tong · Children'S Hosp Of Philadelphia · R01 · FY2024 · CA
Pre- and Postgraduate training in Molecular Hematology
$519,916J Evan Sadler · Washington University · T32 · FY2011 · HL
Screening for Resistant Enteric Bacteria to Personalize Infection Prevention Strategies in Neutropenic Patients
$519,904Michael Joseph Satlin · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · AI
Mechanisms of enhancer regulation in leukemia
$519,834Iannis Aifantis · New York University School Of Medicine · R01 · FY2019 · CA
Identifying and exploiting therapeutic vulnerabilities of tumor-host interactions that drive bone-to-meninges breast cancer metastasis
$519,766Dorothy A Sipkins · Duke University · R01 · FY2023 · CA
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease
$519,750Juan Fernando Vera · Marker Therapeutics, Inc. · R01 · FY2024 · FD
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease
$519,750Juan Fernando Vera · Marker Therapeutics, Inc. · R01 · FY2022 · FD
HLA-DR Targeted Synthetic High Affinity Ligands
$519,709Gerald L Denardo · University Of California At Davis · P01 · FY2006 · CA
Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL
$519,672Nadia Carlesso · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Genetic and molecular basis for SRSF2 mutations in myelodysplasia
$519,636Robert K Bradley · Fred Hutchinson Cancer Research Center · R01 · FY2021 · HL
Clinical Program
$519,497William George Wierda · University Of California, San Diego · P01 · FY2016 · CA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies
$519,480Lee Roy Morgan · Dekk-Tec, Inc. · R44 · FY2019 · CA
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
$519,368Steven Mark Albelda · University Of Pennsylvania · P01 · FY2018 · CA
Genetic Dissection of Drosophila Hematopoiesis
$519,205University Of California Los Angeles · R01 · FY2005 · HL
Hematopoiesis in germline RUNX1mutation carriers: impact of inflammation and the bone marrow niche
$519,194Anupriya Agarwal · Oregon Health & Science University · R01 · FY2022 · HL
Investigating the heterogeneous aging of individual hematopoietic stem cell clones
$519,024Rong Lu · University Of Southern California · R01 · FY2019 · HL
Investigating the heterogeneous aging of individual hematopoietic stem cell clones
$519,024Rong Lu · University Of Southern California · R01 · FY2018 · HL
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia
$518,975Thomas J. O'Hare · University Of Utah · R01 · FY2017 · CA
Novel CART Cells for Treating AML
$518,949Xianxin Hua · University Of Pennsylvania · R01 · FY2025 · CA
Inhibition of Bcl-xL by Targeted Degradation
$518,840Guangrong Zheng · University Of Florida · R01 · FY2020 · CA
Microbiota-focused strategies to mitigate GVHD
$518,709Robert Jenq · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · HL